Clinical trials: Depressive Disorder, Major Depressive Disorder
Treatment Resistant Depression, Major Depressive Episode
University of Iowa Interventional Psychiatry Service Patient Registry
The purpose of this study is to examine the effects of interventional/procedural therapies for treatment-resistant depression (TRD) and Obsessive-Compulsive Disorder (OCD).
- Conditions
- Treatment Resistant Depression, Major Depressive Episode, Major Depression, Major Depressive Disorder
- Trial name
- NCT04480918
- Testing
- Electroconvulsive Therapy (ECT), Transcranial Magnetic Stimulation (TMS), Ketamine
- Where
- United States
- Volunteers
- 1,000 people
- Sponsor
- Mark Niciu
Anxiety, Depression - Major Depressive Disorder
Profiling Vulnerability and Resilience for Mental Illness Following Viral Infections: Translating Epidemiology to Deep-phenotyping.
The study protocol was submitted to ERA-NET NEURON for funding on 28/06/2023. Description of the Israeli responsibilities was extracted from the full submitted research protocol. The protocol includes two studies (CHS1 and CHS2).
- Conditions
- Anxiety, Depression - Major Depressive Disorder, Bipolar, Schizophenia Disorder
- Trial name
- Viral-MI (NCT07453420)
- Where
- Israel
- Volunteers
- 100,000 people, healthy volunteers welcome
- Sponsor
- Shalvata Mental Health Center
Major Depressive Disorder
The Efficacy of Probiotic Compared With Placebo Commitment Therapy for Treatment of Major Depressive Disorder
The purpose of this study is to evaluate the efficacy of oral administration of probiotic at 9 log CFU/day as adjunctive treatment in reducing the severity of depression in female patients with major depressive disorder with…
- Trial name
- NCT05315401
- Testing
- Probiotic, Acceptance and commitment therapy (ACT)
- Where
- Malaysia
- Sponsor
- Min-Tze LIONG
Depression, Major Depressive Disorder
Relapse-Prevention Study With Levomilnacipran ER (F2695 SR) in Patients With Major Depressive Disorder
The purpose of this study is to evaluate the safety and efficacy of Levomilnacipran ER relative to placebo in the prevention of depression relapse in patients with major depressive disorder (MDD).
- Trial name
- NCT01085812
- Testing
- Levomilnacipran ER
- Where
- 35 sites in United States, Canada
- Volunteers
- 734 people
- Sponsor
- Forest Laboratories
Major Depressive Disorder
Intradermal Acupuncture Based on Changes in Biological Specificity of Acupoints for Major Depressive Disorder
Acupoints are the stimulus points and reactive points for acupuncture to treat diseases. Therefore, this study is designed to detect the pain threshold and temperature of biological specificities of acupoints in healthy control…
- Trial name
- NCT05524519
- Testing
- Basic treatment, PSA, TSA
- Where
- China
- Volunteers
- 160 people, healthy volunteers welcome
- Sponsor
- The Third Affiliated hospital of Zhejiang Chinese Medical University
Amphetamine Abuse, Amphetamine Dependence
A Pilot Study of Citicoline add-on Therapy in Patients With Bipolar Disorder or Major Depressive Disorder and Amphetamine Abuse or Dependence
Bipolar disorder (BD) is a common and severe psychiatric illness. Drug and alcohol abuse are very common in people with BD and other mood disorders and are associated with increased rates of hospitalization, violence towards self…
- Conditions
- Amphetamine Abuse, Amphetamine Dependence, Bipolar Disorder, Major Depressive Disorder
- Trial name
- NCT00377299
- Testing
- Citicoline
- Where
- United States
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- University of Texas Southwestern Medical Center
Major Depressive Disorder
Cysteamine Therapy for Major Depressive Disorder
The purpose of this study is to determine whether cysteamine bitartrate, an FDA-approved drug for a non-psychiatric condition, is safe and effective for the treatment of major depression.
- Trial name
- NCT00715559
- Testing
- cysteamine bitartrate
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- Icahn School of Medicine at Mount Sinai
Major Depression Disorder, Cognitive Deficits
Neuromodulation and Attention Deficits in MDD
Multimodal study (Behavior, TMS, EEG) combining a sham-controlled intermittent theta burst stimulation (iTBS) intervention with an additional-singleton task and EEG to evaluate whether left dorsolateral prefrontal cortex (DLPFC)…
- Conditions
- Major Depression Disorder, Cognitive Deficits, Selective Attention
- Trial name
- NCT07111169
- Testing
- intermittent theta burst stimulation (iTBS) intervention
- Where
- China
- Volunteers
- 60 people
- Sponsor
- University of Electronic Science and Technology of China
Major Depressive Disorder
A Study to Evaluate BMS-986511 in Adults With Major Depressive Disorder
A Study to Evaluate BMS-986511 in Adults with Major Depressive Disorder
- Trial name
- NCT07772531
- Testing
- BMS-986511
- Where
- 27 sites in United States, Czechia
- Volunteers
- 200 people
- Sponsor
- Bristol-Myers Squibb
Major Depressive Disorder, Anxiety Disorders
Sensitivity of Short and Long Allele Carriers of the 5-HTTLPR to Environmental Threat Post Hydrocortisone Administration
The current study will test the causal relationship between elevated levels of cortisol and the serotonin transporter gene (5-HTTLPR) as these factors influence sensitivity to environmental threat.
- Trial name
- 5-HTTLPR (NCT01710202)
- Testing
- Hydrocortisone
- Where
- 2 sites in United States
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- University of Texas at Austin
Depression - Major Depressive Disorder, Catatonia
Optimizing Stimulation Parameters for Electroconvulsive Therapy
The goal of this clinical trial is to improve how electroconvulsive therapy (ECT) stimulation settings are chosen. Researchers will use real-time brain monitoring to measure both seizures and a recently identified brain event…
- Trial name
- PRESTO (NCT07561307)
- Testing
- Electroconvulsive Therapy
- Where
- United States
- Volunteers
- 64 people
- Sponsor
- University of Pennsylvania
Major Depressive Disorder
Study Comparing Adjunctive Risperidone Versus Placebo in Major Depressive Disorder That Is Not Responding to Standard Therapy
The purpose of this trial is to evaluate the efficacy and safety of risperidone versus placebo in subjects with Major Depressive Disorder with sub-optimal response to antidepressant therapy.
- Trial name
- NCT00095134
- Testing
- risperidone
- Where
- 70 sites in United States
- Volunteers
- 630 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Multiple Sclerosis, Spinal Cord Injury
Motivational Interviewing to Increase Physical Activity to Treat Depression in People Aging With MS or SCI
This study compares two approaches to helping people who are aging with MS or SCI and are experiencing depressed mood to become more physically active. The study is carried out entirely by telephone.
- Trial name
- inMotion (NCT00947232)
- Testing
- Motivational interviewing, Education
- Where
- United States
- Volunteers
- 123 people
- Sponsor
- University of Washington
Treatment Resistant Depression
Ketamine Frequency Treatment for Major Depressive Disorder
Depression is a wide spread illness. Depression contributes most significantly to national health care costs. While the number and types of treatments used for depression have expanded over the years, even with an increased range…
- Trial name
- NCT00646087
- Testing
- Ketamine, Ketamine/Saline
- Where
- United States
- Volunteers
- healthy volunteers welcome
- Sponsor
- Essentia Health
Major Depressive Disorder, Treatment-Resistant Depression
Antidepressant Effects of TS-161 in Treatment-Resistant Depression
Background: Major depressive disorder (MDD) is a common, chronic mental illness. It can take weeks to months for antidepressants to work. Researchers want to test a new drug that might act more rapidly.
- Conditions
- Major Depressive Disorder, Treatment-Resistant Depression, Depression
- Trial name
- NCT04821271
- Testing
- TS-161
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- National Institute of Mental Health (NIMH)
Major Depressive Disorder
The Relationship Among Changes in Brain Network Activation in Adult Outpatients With Major Depressive Disorder
The purpose of this study is to explore patterns of Brain Network Activation (BNA) changes from baseline to endpoint on 1) efficacy of core symptoms of Major Depressive Disorder (MDD) and 2) improvement of cognitive dysfunction…
- Trial name
- NCT02749721
- Testing
- vortioxetine
- Where
- 2 sites in United States
- Volunteers
- 31 people
- Sponsor
- Rush University Medical Center
Depression, Unipolar, Depression Moderate
The Cerebral and Cognitive Changes After Intermittent Theta Burst Stimulation (iTBS) Treatment for Depression
The present project aims to assess the neurocognitive impact of a two-week once-a-day regimen of intermittent theta burst stimulation (iTBS) compared to sham iTBS, when targeting the left dorsolateral prefrontal cortex (LDLPFC)…
- Trial name
- NCT06534684
- Testing
- Intermittent Theta Burst Stimulation
- Where
- Norway
- Volunteers
- 50 people
- Sponsor
- University Hospital of North Norway
Major Depressive Disorder, Treatment Resistant Depression
Identifying Local Field Potential Biomarkers for Treatment-Resistant Major Depression With Deep Brain Stimulation
Major depressive disorder (MDD) is a complex and severe mental illness, characterized by multiple symptoms, and is a leading cause of non-fatal health loss.
- Trial name
- NCT06542094
- Testing
- Deep Brain stimulation
- Where
- China
- Volunteers
- 12 people
- Sponsor
- West China Hospital
Major Depressive Disorder (MDD), Generalized Anxiety Disorder (GAD)
Validation of the CIDI 5.0 Against the SCID-5 for Lifetime Mental Disorders
The World Health Organization Composite International Diagnostic Interview (CIDI) is a fully structured diagnostic tool designed for lay interviewers to assess the prevalence of mental and substance use disorders.
- Conditions
- Major Depressive Disorder (MDD), Generalized Anxiety Disorder (GAD), Posttraumatic Stress Disorder (PTSD)
- Trial name
- NCT07604753
- Testing
- CIDI-5
- Where
- Hong Kong
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- The University of Hong Kong
Major Depressive Disorder
Treatment of Patients With Major Depressive Disorder With MK0869 (0869-063)
A clinical study to determine the efficacy and safety of MK0869 in the treatment of depression.
- Trial name
- NCT00034944
- Testing
- MK0869, aprepitant
- Volunteers
- 495 people
- Sponsor
- Merck Sharp & Dohme LLC